Compounds > nafamostat
Page last updated: 2024-10-31

nafamostat and Acute Hepatic Failure

nafamostat has been researched along with Acute Hepatic Failure in 2 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nakae, H2
Igarashi, T1
Tajimi, K2
Yonekawa, C1
Zheng, YJ1
Wada, H1
Tanaka, H1

Trials

1 trial available for nafamostat and Acute Hepatic Failure

ArticleYear
The dose of nafamostat mesilate during plasma exchange with continuous hemodiafiltration in the series-parallel circuit.
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2006, Volume: 10, Issue:3

    Topics: Aged; Anticoagulants; Benzamidines; Biomarkers; Dose-Response Relationship, Drug; Female; Guanidines

2006

Other Studies

1 other study available for nafamostat and Acute Hepatic Failure

ArticleYear
IL-15 levels in patients with acute hepatic failure.
    Research communications in molecular pathology and pharmacology, 2004, Volume: 115-116

    Topics: Adult; Aged; Anticoagulants; Benzamidines; Bilirubin; Enzyme-Linked Immunosorbent Assay; Female; Gua

2004